TARGETING MITOCHONDRIA

Mitochondria are pertinent targets for efficient drugs, cosmetics or functional food for better health and safer products. Find out how our tests can help advance your projects in demonstrating mechanisms of action and getting pre-clinical proof of principle.

Learn more about it
BLOOD MARKERS FOR DEMENTIA

ICDD is set to identify blood makers specifically for presymptomatic stages of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington’s disease using cellulomics in innovative patient-derived cell models & blood protein profiling.

Learn more about it
PARTNER WITH US         

You have a drug that target CNS diseases and cancers. We have companion diagnostic tests and platforms to identify subset of patients that respond to and tolerate your drug. Let’s work together to advance patient health and disease clinical management.

Learn more about it
The Science of Possibility

HARNESSING THE POWER OF SYSTEM BIOLOGY

Understanding complex processes and their dynamics is how ICDD progresses toward the identification of new candidate biomarkers associated with disease progression and/or drug response.

EVENTS

Pierre Fabre's Day One
ICDD will present its Cancer Profiler at Pierre Fabre's open innovation event, Day One, in Toulouse. Join us there to learn all about it!
In‑Cosmetics Paris
Thank you to everyone who visited us on our stand and to those who participated in our quiz! See you next year in London!

What we do

  • Disease modeling through mitochondrial dysfunction

  • Comprehensive assessment of cell metabolism in a multiplexed fashion

  • Assessment of mitochondrial liabilities

  • Identify whether ROS production is damageable in your system

  • Performances of mtDNA control

  • Selecting disease-modifying drugs for CNS

  • Profiling clinical tolerance at the pre-clinical stage

  • Personalized medicine diagnostic co-development

  • Molecular determinants of drug response & tolerance

  • They support us